Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States

ConclusionIn the real-world setting, patients with NVAF newly treated with apixaban were less likely to switch or discontinue treatment compared to patients treated with rivaroxaban or dabigatran.FundingPfizer and Bristol-Myers Squibb.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research